EP2563120B1 - Compositions comprising triiodothyronine and an anti-thyroid agent for the treatment of cancer - Google Patents

Compositions comprising triiodothyronine and an anti-thyroid agent for the treatment of cancer Download PDF

Info

Publication number
EP2563120B1
EP2563120B1 EP11774538.0A EP11774538A EP2563120B1 EP 2563120 B1 EP2563120 B1 EP 2563120B1 EP 11774538 A EP11774538 A EP 11774538A EP 2563120 B1 EP2563120 B1 EP 2563120B1
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
thyroid
subject
ptu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11774538.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2563120A4 (en
EP2563120A1 (en
Inventor
Osnat Ashur-Fabian
Aleck Hercbergs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2563120A1 publication Critical patent/EP2563120A1/en
Publication of EP2563120A4 publication Critical patent/EP2563120A4/en
Application granted granted Critical
Publication of EP2563120B1 publication Critical patent/EP2563120B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Definitions

  • the present invention relates to compositions and kits for treating cancer.
  • T 4 The thyroid hormones thyroxine (T 4 ) and triiodothyronine (T 3 ) play a significant role in the growth, development and differentiation of normal cells.
  • Thyroxine (3,5,3',5'-tetraiodothyronine, T 4 )
  • T 4 is the major hormone secreted by the follicular cells of the thyroid gland.
  • Triiodothyronine, (T 3 ) is a thyroid hormone similar to T 4 but with one fewer iodine atoms per molecule.
  • Thyroid-stimulating hormone (TSH) secreted from the hypophisis, controls the production of T 4 and T 3 . In the thyroid, T 4 is converted to T 3 , however, most of the circulating T 3 is formed peripherally by deiodination of T 4 (85%). Thus, T 4 acts as prohormone for T 3 .
  • T 4 is the standard thyroid hormone used for replacement therapy in patients with hypothyroidism [1]. T 4 in combination with T 3 for treatment of clinical hypothyroidism was reviewed [2]. T 4 in combination with T 3 or T 4 alone have also been used to treat various mood disorders such as unipolar depression [3] and major depression. T 3 alone (at daily doses of 25-50 ⁇ g for 4 weeks) was found to be effective in treating depression in patients non-responsive to serotonin selective reuptake inhibitors [4]. Further, T 3 (20-25 ⁇ g per day for 1 week; 40-50 ⁇ g/day thereafter) was combined with Sertalin to treat depression [5].
  • thyroid hormones may positively modulate neoplastic cells.
  • lowering the levels of thyroid hormones i.e. by introducing a hypothyroid state
  • Hercbergs and Leith reported on a patient suffering from metastatic lung cancer in which spontaneous remission of his cancer was documented, following a myxedema coma episode (extremely low levels of thyroid hormones) [7].
  • Cristofanilli M, et al. pointed to a reduced risk and significantly older age at onset /diagnosis of primary breast carcinoma in patients suffering from primary hypothyroidism [12].
  • Theodossiou C, et al. indicates that human lung and prostate tumors do not grow well in hypothyroid nude mice. [13].
  • Mendeleyev J, et al. described a method of treating a malignant tumor using a T 4 analogue having no significant hormonal activity [14].
  • Hercbergs A, et al. describe that propylthiouracil-induced chemical hypothyroidism with high dose tamoxifen prolonged survival in recurrent high grade glioma. [15]. Hercbergs A also found a highly significant correlation between a free thyroxine decline below the reference range and the six month progression free survival [16].
  • Japanese patent application No. 63-79824 [17] describes carcinostatic agents comprising as active ingredients iodotyrosine, such as monoiodotyrosine (MIT) and diiodotyrosine (DIT); and/or iodothyronine, such as triiodothyronine (T 3 ) and iodothyroxinee (T 4 ).
  • iodotyrosine such as monoiodotyrosine (MIT) and diiodotyrosine (DIT)
  • iodothyronine such as triiodothyronine (T 3 ) and iodothyroxinee (T 4 ).
  • the dosage range described for MIT and DIT is 10 mg to 10g/day per 50 kg body weight, to be administered by intravenous injection or orally; and with regard to T 3 and T 4 , administration includes IV injection in the range from 1 ⁇ g to 1 mg/day per 50 kg body weight, preferably using both in dosages from 0.1 mg/day per 50 kg body weight to 25 ⁇ g/day, and even more preferably oral administration of tyrosine and iodine in dosages of 10 mg to 10 g/day per 50 kg body weight.
  • T 4 affects cell division and angiogenesis through binding to integrin ⁇ V ⁇ 3, commonly overexpressed on many cancer cells [18].
  • the present invention provides a pharmaceutical combination comprising:
  • the biochemical analogue may be an L-isomer of T 3 , preferably, liothyronine sodium.
  • the anti-thyroid agent may be a thioamide based drug, such as, propylthiouracil (PTU) or methimazole.
  • PTU propylthiouracil
  • the pharmaceutical combination may comprise Methimazole in an amount for daily administration of between 10mg and 80mg, or PTU in an amount for daily administration of between 100mg and 1200mg.
  • the present invention is based on the following empirical findings:
  • composition for use in a therapeutic method comprising administering to a subject in need of a therapeutic treatment with:
  • the term "biochemical analogue" of T 3 denotes any compound having a thyronine backbone and exhibits at least partial T 3 hormonal activity.
  • the T 3 biochemical analogue is an L-isomer of T 3 .
  • the T 3 biochemical analogue is an iodine derivative of thyronine.
  • the T 3 biochemical analogue is an L-isomer of T 3 is liothyronine sodium.
  • the biochemical analogue is an iodine derivative of thyronine.
  • iodinated derivatives may be prepared by methods known in the art, such as that described by Gunther Hillman in Great Britain patent No. GB 851,610 titled: Methods of producing iodine derivatives of thyronine.
  • iodine derivatives of thyronine include 3',5',3-triiodothyronine (rT 3 ), rT 3 derived hormone, such as 3',3-diiodothyronine, 3',5'-diiodothyronine, 5',3- diiodothyronine, 3'-iodothyronine, 5'-iodothyronine, 3-iodothyronine, 3'-bromo-5'-iodo-3,5-di-iodothyronine, 3'-chloro--5'-iodo-3,5-diiodothyronine, isomer of 3,5,3 '-triiodothyronine, e.g.
  • the biochemical analogue is Liothyronine sodium being the L-isomer of triiodothyronine (LT 3 ), (marketed under the brand name Cytomel® or Tertroxin® in Australia).
  • biochemical analogues may include amides of iodothyronine compounds, such as those described by Cree Gavin et al. in US patent No. 4,426,453 titled: Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds.
  • the biochemical analogue of T 3 exhibit at least partially T 3 hormonal activity sufficient to, for example, signal the hypophysis that there is enough T 3 in the circulation and resulting in reduction of T 4 production.
  • anti-thyroid treatment is used to denote treatment with an anti-thyroid agent, treatment with radioiodine (I 131 ) to destroy the thyroid gland or thyroidectomy treatment to remove part or all of the thyroid gland (thyroidectomy treatment may consist of hemithyroidectomy (or “unilateral lobectomy") in which only half of the thyroid is removed or isthmectomy in which the band of tissue (or isthmus) connecting the two lobes of the thyroid is removed).
  • the anti-thyroid agent is any chemical or biological agent that is capable of decreasing the amount of thyroid hormone produced by the thyroid gland.
  • anti-thyroid agents There are a variety of anti-thyroid agents known in the art.
  • the anti-thyroid agent is a thioamide based drug.
  • the anti-thyroid agent is selected from propylthiouracil (PTU), methimazole (also known as Tapazole® or Thiamazole®) and Carbimazole.
  • PTU propylthiouracil
  • methimazole also known as Tapazole® or Thiamazole®
  • Carbimazole is selected from propylthiouracil (PTU), methimazole (also known as Tapazole® or Thiamazole®) and Carbimazole.
  • the method of the invention comprises administration of Methimazole in an amount between 10mg and 80mg per day, or of PTU in an amount of between 100mg and 1200mg per day.
  • the term " treatment ", " treating " or any lingual variation thereof, is used herein to refer to obtaining a desired pharmacological and physiological effect on the subject's well being.
  • the effect may be prophylactic in terms of preventing or partially preventing an undesired condition or undesired symptoms in the subject in predisposition of developing the condition and/or may be therapeutic in terms of curing or partially curing of an already existing undesired condition, symptom or adverse effect attributed to the condition.
  • the term “treatment ", as used herein, covers any of the following (a) preventing the condition from occurring in a subject which may be predisposed to have the condition (e.g.
  • cancer but has not yet been diagnosed as having it, e.g. the clinical symptoms of the condition have not yet being developed to a detectable level; (b) inhibiting the condition from developing or its clinical symptoms, such as fever or inflammation; or (c) causing regression of the condition and/or its symptoms.
  • composition of the present invention is effective to treat a subject having cancer.
  • the treatment may be effective to achieve at least one of the following:
  • sensitization to anti cancer treatment is used to denote an effect of treatment with the at least one anti-thyroid treatment and T 3 or biochemical analogue thereof that results in a statistically significant sensitivity of the cancer cells to anti-cancer treatment.
  • sensitization may include increase in sensitivity of the cancer cells to the anti-cancer treatment as well as causing drug resistant cells to become sensitive to the anti-cancer treatment (e.g. in case of multidrug resistant cells).
  • sensitization may thus permit reduction in a required amount of anti cancer treatment (such as chemotherapeutic drug or radiotherapy) that would be otherwise required without sensitization.
  • the anti-cancer treatment may be one or more selected from the group consisting of chemotherapy, radiotherapy monoclonal antibody therapy, angiogenesis inhibitor therapy, biological therapy, bone marrow transplantation, peripheral blood stem cell transplantation, gene therapy for cancer, hyperthermia, laser therapy, photodynamic therapy, and targeted cancer therapies.
  • Chemotherapy comprises treatment with one or more chemotherapeutic drug selected from alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, or any other antitumor agents which affect cell division or DNA synthesis and function in some way.
  • chemotherapeutic drug selected from alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, or any other antitumor agents which affect cell division or DNA synthesis and function in some way.
  • chemotherapeutic drugs which are used in the context of the present invention include Amsacrine (Amsidine®); Bleomycin, Busulfan, Capecitabine (Xeloda®), Carboplatin, Carmustine (BCNU®), Chlorambucil (Leukeran®), Cisplatin, Cladribine (Leustat®), Clofarabine (Evoltra), Crisantaspase (Erwinase®), Cyclophosphamide, Cytarabine (ARA-C), dacarbazine (DTIC®), Dactinomycin (Actinomycin D®), Daunorubicin Docetaxel (Taxotere®), Doxorubicin, Epirubicin, Etoposide (Vepesid®, VP-16®), Fludarabine (Fludara®), Fluorouracil (5-FU®), Gemcitabine (Gemzar®), Hydroxyurea (Hydroxycarbamide,
  • compositionof the invention may also be effective to treat cancer cells.
  • Treatment of cancer cells is to be understood as any effect on the cells that results in one or more of reducing the volume of the cancer cells, inhibiting or causing cession of proliferation of the cancer cells, causing cancer cell death (e.g. apoptosis, necrosis etc), eliminating the cells from the subject's body, inducing cell cycle arrest.
  • cancer which is used interchangeably with the term “ cancer cells” refers to any type of cells that are associated with the formation of a cancerous tumor.
  • the cancer may be selected from the group consisting of carcinoma, sarcoma, lymphoma and leukemia, germ cell tumor and blastoma.
  • the cancer cells treated by the composition of the invention can be those associated with solid tumors or liquid tumors.
  • Non-limiting examples of solid tumors include wherein the solid cancer is selected from the group consisting of vascularized tumors, gonadal cancers, gastrointestinal, esophageal cancer, Barrett's esophagus cancer, oral cancer, parotid cancer, nasopharyngeal cancer, thyroid cancer, CNS cancers, urogenital cancers, skin cancers bone and connective tissue cancers.
  • the solid cancer is glioma, e.g. glioblastoma.
  • Non-limiting examples of liquid tumors include multiple myeloma, Waldenstroms' (IgM) gammopathy, Bergers (IgA), CNS lymphoma (e.g., associated with AIDS), gonadal lymphomas and leukemias, mantle cell lymphomas, vascularized stages of leukemias (bone marrow) and lymphomas (in the lymph nodes), and any other leukemia or lymphoma, including low grade leukemias and lymphomas.
  • IgM Waldenstroms'
  • Bergers IgA
  • CNS lymphoma e.g., associated with AIDS
  • gonadal lymphomas and leukemias e.g., associated with AIDS
  • gonadal lymphomas and leukemias e.g., associated with AIDS
  • gonadal lymphomas and leukemias e.g., associated with AIDS
  • gonadal lymphomas and leukemias e.g., associated with AIDS
  • the cancer cells may be malignant cancer cells.
  • the composition may be administered as T 3 or the analogue thereof simultaneously, concomitantly or separately, e.g. within a time interval from the anti-thyroid treatment.
  • the composition of the invention may be used in continuous treatment of the subject for a period of at least 4 weeks.
  • composition of the present invention may be administered in conjunction with other treatments.
  • the composition of the invention may be administered in conjugation with one other anti-cancer therapy (e.g. chemotherapy, radiotherapy, hyperthermia, biologic therapy).
  • the composition may be administered in conjunction with another therapy which is not directly aimed at the treating of cancer (e.g., surgery, hormone replacement therapy).
  • the use of the invention is, in accordance with some embodiments, for treating a subject having cancer or for the preparation of a pharmaceutical composition for treating cancer, the treatment and cancer being as defined hereinabove.
  • kits comprising:
  • the instructions comprise administering the T 3 or a biochemical analogue thereof and the at least one anti-thyroid agent to a subject having cancer.
  • the kit of the invention is applicable, in accordance with some embodiments of the invention, to provide the dosage form of T 3 or a biochemical analogue thereof and the dosage form of the at least one anti-thyroid agent; in an amount are sufficient to achieve one or more effect selected from:
  • the T 3 or analogue thereof and the anti-thyroid agent may be provided to the subject in need thereof separately, or in a single composition.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • the composition is for treating cancer, the cancer being as defined hereinabove.
  • composition is effective to achieve one or more of:
  • the T 3 or analogue thereof and the anti-thyroid agent may be provided to the subject in various forms, including gastrointestinal administration (e.g. oral in tablets, capsules, drops, syrup or suspension); rectal; by mean of gavage; sublingual; sublabial; administration through the central nervous system (e.g. epidural, intracerebral, intracerebroventricular), administration via other locations such as epicutaneous, intradermal, subcutaneous, nasal, intravenous, intraarterial, intramuscular, intracardiac, intraosseous infusion, intrathecal, intraperitoneal, intravesical, intravitreal, intracavernous injection, intravaginal and intrauterine.
  • gastrointestinal administration e.g. oral in tablets, capsules, drops, syrup or suspension
  • rectal by mean of gavage
  • sublingual sublabial
  • administration through the central nervous system e.g. epidural, intracerebral, intracerebroventricular
  • administration via other locations such as epicutaneous, intradermal, subcutaneous, nasal, intra
  • the T 3 or analogue thereof and the anti-thyroid agent are provided together or separately in one or more formulations suitable for oral administration, such as, without being limited thereto, pills, tablets, capsules, suspension, syrups, drops etc.
  • an anti-thyroid agent may independently include a plurality of agents, including a variety thereof.
  • the term " comprising” is intended to mean one or more of the recited elements.
  • the term " consisting essentially of " is used to define the recited elements while excluding other elements. " Consisting of " shall thus mean excluding more than trace amounts of elements that are not recited. Embodiments defined by each of these transition terms are within the scope of this invention.
  • hypothyroidism induced by anti thyroid drugs such as PTU or Metimazole combined with T 3 (Cytomel®): These examples will show that anti-thyroid treatment such as PTU/methimazole in combination with T 3 or analogue thereof, induce a quick (2-4 weeks) decrease in FT 4 levels.
  • MRI Magnetic Resonance Imaging
  • GBM characteristic grade IV glioblastoma
  • the subject was initially treated with the standard protocol for newly diagnosed GBM, which included focal radiation with concurrent oral administration of temozolomide, followed by 9 cycles of monthly 5-day regimen of temozolomide treatment. During that time a further decline in vision was observed as well as an increased tumor size observed on MRI ( Figures 1E-1H ).
  • a female subject was presented with a malignant fibrous histiocytoma (MFH) of the left pulmonary vein.
  • the tumor filled the left chest cavity and invaded the left atrium.
  • the tumor was resected but recurred within 4 months.
  • the subject then underwent resection of the mass which was found to be mostly necrotic.
  • the subject was maintained on Cytomel® 5 ⁇ g, three times a day and methimazole (reduced to 30 mg once a day).
  • the subject exhibited excellent post operative performance status and returned to work.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP11774538.0A 2010-04-28 2011-04-28 Compositions comprising triiodothyronine and an anti-thyroid agent for the treatment of cancer Active EP2563120B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (3)

Publication Number Publication Date
EP2563120A1 EP2563120A1 (en) 2013-03-06
EP2563120A4 EP2563120A4 (en) 2015-05-13
EP2563120B1 true EP2563120B1 (en) 2020-02-26

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11774538.0A Active EP2563120B1 (en) 2010-04-28 2011-04-28 Compositions comprising triiodothyronine and an anti-thyroid agent for the treatment of cancer

Country Status (11)

Country Link
US (2) US9655984B2 (enExample)
EP (1) EP2563120B1 (enExample)
JP (1) JP5921529B2 (enExample)
KR (1) KR101841304B1 (enExample)
CN (1) CN102858156B (enExample)
AU (1) AU2011246851B2 (enExample)
BR (1) BR112012027463A2 (enExample)
CA (1) CA2797625C (enExample)
ES (1) ES2791708T3 (enExample)
MX (1) MX2012012479A (enExample)
WO (1) WO2011135574A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院（天津医科大学肿瘤医院） T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6939863B2 (en) * 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
JP2009507847A (ja) * 2005-09-08 2009-02-26 シャイア エルエルシー 生体利用性を増強したｔ３及びｔ４のプロドラッグ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
AU2011246851A1 (en) 2012-11-15
MX2012012479A (es) 2013-07-03
EP2563120A4 (en) 2015-05-13
BR112012027463A2 (pt) 2015-09-29
EP2563120A1 (en) 2013-03-06
US20170274104A1 (en) 2017-09-28
JP5921529B2 (ja) 2016-05-24
CA2797625A1 (en) 2011-11-03
US10398789B2 (en) 2019-09-03
AU2011246851B2 (en) 2016-07-21
KR20130103336A (ko) 2013-09-23
JP2013525422A (ja) 2013-06-20
US9655984B2 (en) 2017-05-23
ES2791708T3 (es) 2020-11-05
US20130129615A1 (en) 2013-05-23
CA2797625C (en) 2019-08-20
CN102858156B (zh) 2015-09-23
WO2011135574A1 (en) 2011-11-03
KR101841304B1 (ko) 2018-03-22
CN102858156A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
US10398789B2 (en) Methods, compositions and kits for providing a therapeutic treatment
EP1778215B1 (en) Anticancer effect enhancer
ES2881928T3 (es) Profármacos de etopósido para su uso en el direccionamiento a las células madre cancerosas
KR20060097000A (ko) 화학요법제와 ｖｅｇｆ 수용체 저해제의 배합물
Wang et al. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
JPWO2012111790A1 (ja) 化学療法剤の抗腫瘍活性増強剤
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
Liu et al. Rapamycin liposomes combined with 5-fluorouracil inhibits angiogenesis and tumor growth of APC (Min/+) mice and AOM/DSS-induced colorectal cancer mice
WO2009128805A1 (en) On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors
KR101843985B1 (ko) 암을 치료하기 위한 조성물과 방법
TW201728334A (zh) 用於治療癌症之組合物及方法
US10751352B2 (en) Pharmaceutical composition for preventing or treating cancer
KR20040048992A (ko) 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
RU2706341C1 (ru) Способ лечения неоперабельной аденокарциномы головки поджелудочной железы
CN107569485A (zh) 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
RU2724341C1 (ru) Комбинированная композиция для предупреждения или лечения рака, содержащая производные бензофенонтиазола в качестве vda и ингибитор топоизомеразы
WO2014047398A1 (en) Modulation of asymmetric proliferation
AU2010336256A1 (en) Antitumor Agent or Postoperative Adjuvant Chemotherapeutic Agent for Hepatocellular Carcinoma Treatment
Li et al. Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer
CN109303919B (zh) Akt抑制剂在制备增强石蒜碱的抗肝癌活性药物中的应用
Nakatani et al. Effects of Combination Chemotherapy with Cepharanthin on Oral Squamous Cell Carcinoma
CN119792538A (zh) 胶质母细胞瘤的新的治疗方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150415

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4164 20060101ALI20150407BHEP

Ipc: A61K 31/513 20060101ALI20150407BHEP

Ipc: A61K 31/198 20060101AFI20150407BHEP

Ipc: A61K 45/06 20060101ALI20150407BHEP

Ipc: A61P 35/00 20060101ALI20150407BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171004

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190529

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011065238

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1236795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200526

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200415

Year of fee payment: 10

Ref country code: ES

Payment date: 20200504

Year of fee payment: 10

Ref country code: FR

Payment date: 20200414

Year of fee payment: 10

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200626

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200527

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200528

Year of fee payment: 10

Ref country code: GB

Payment date: 20200416

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200719

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2791708

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201105

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1236795

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200226

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011065238

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

26N No opposition filed

Effective date: 20201127

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011065238

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210430

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210428

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200226

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220728

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210428